Studies involving inbred strains (classical)




Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Ackert1 body size and weight Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. None BMI, BW inbred  (32) both 26, 52, 87 wks 2008
Ackert1 DXA Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. bone area, body area BMD inbred  (32) both 26, 52, 87 wks 2008
Albers1 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL, triglycerides, phospholipids. 4h fast, plasma. Baseline vs. high-fat diet (6wks). None PL, TG inbred  (15) both 6-14wks 1999
Albers1 protein activity assessment
with high-fat diet
Phospholipid transfer protein activity. 4h fast. None PL inbred  (15) both 6-14wks 1999
Bachmanov1 body weight Body weight None BW inbred  (13) m 7-8wks 2011
Bachmanov1 bottle choice test Sodium chloride solution taste threshold. Fluid intake. None NaCl inbred  (13) m 7-8wks 2011
Bachmanov1 intake monitoring Water intake. Daily. None None inbred  (13) m 7-8wks 2011
Benavides1 genotype assessment Gpr84 allele assessment. PCR, sequencing. None None inbred w/CC8  (58) both 6wks 2013
Benoist1 immune cell quantification Regulatory T cells (Treg), thymus, spleen. CD25hi, Foxp3+ None inbred  (33) m 5-6wks 2007
Berndt1 ventilator
with methacholine
Airway resistance. Baseline vs. methacholine-challenged (several doses). None MCh inbred  (37) both 9-12wks 2010
Berndt2 plethysmography
with methacholine
Lung, respiratory function. Baseline vs. methacholine-challenged (several doses). Breathing patterns: efficiency, cycle, airflow, enhanced pause, airway resistance MCh inbred  (29) both 9-12wks 2010
Berndt2 ventilator
with methacholine
Lung, respiratory function. Anesthetized forced oscillation. Baseline vs. methacholine-challenged (several doses). Lung volume, compliance, airflow, airway resistance MCh inbred  (29) both 9-12wks 2010
Berndt3 metabolite quantification Vitamin D concentration (serum). None None inbred  (18) m 11wks 2011
Berndt4 histopathology Lung adenoma frequency and severity at 20mo. Tumor incidence, cancer, aging. None None inbred  (28) both 87wks 2011
Bodnar1 intake monitoring
with sucrose
Food, caloric, water intake. Baseline and with sucrose (several concentrations). 24h test. None None inbred  (12) m 13-17wks 2006
Boon1 body weight
with influenza A (H5N1) virus
Influenza A (H5N1) virus (several doses) vs. baseline. None BW, flu inbred  (23) f 6-9wks 2011
Boon1 health assessment
with influenza A (H5N1) virus
Survival rate, influenza A (H5N1) virus (several doses). Strain H5N1 susceptibility score. None flu inbred  (23) f 6-9wks 2011
Bopp1 health assessment
with Plasmodium berghei
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. None None inbred  (31) both 8-12wks 2010
Brayton1 study archive Spontaneous diseases. None None inbred both 2013
Broad2 genotyping SNP profiling, 131,000+ genomic locations, 1-19,X. None SNPs inbred  (89) 2009
Brown1 body weight Body weight None BW inbred  (14) both 10wks 2004
Brown1 elevated plus maze Locomotor, exploratory, and anxiety-related behavior. None EPM inbred  (14) both 10wks 2004
Brown1 elevated zero maze Locomotor, exploratory, and anxiety-related behavior. None EZM inbred  (14) both 10wks 2004
Brown1 light-dark box Anxiety, avoidance behavior. None None inbred  (14) both 10wks 2004
Brown1 open field test Locomotor, exploratory, and anxiety-related behavior. None OFT inbred  (14) both 10wks 2004
Brown2 Barnes circular maze Spatial learning and memory. None None inbred  (14) both 10-18wks 2004
Brown2 Morris water maze Spatial learning and memory. None None inbred  (14) both 10-18wks 2004
Brown2 olfactory discrimination task Olfactory-related learning and memory. None None inbred  (14) both 10-18wks 2004
Brown2 rotarod Latency to fall from accelerating rotarod. 7 day trials. None None inbred  (14) both 10-18wks 2004
Brown2 visual water box Spatial learning and memory. None None inbred  (14) both 10-18wks 2004
Brugnara1 complete blood count Hematology. Red cell corpuscular volume, hemoglobin content, hemoglobin concentration mean, reticulocyte count CBC, RBC, WBC, CHCM, HGB, MCH, MCHC inbred  (10) both 8wks 2013
Brugnara1 ion transport assessment Hematology red cell ion content, ion transport. potassium chloride cotransport, KCC, sodium-potassium pump, sodium-hydrogen exchanger, cations, ion transport KCl inbred  (10) both 8wks 2013
CGD-MDA1 genotyping SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. None SNPs inbred  (142) m 2014
CGDpheno1 body size and weight Body weight and length. None BW inbred  (72) both 10-13wks 2009
CGDpheno1 complete blood count Hematology. Cell counts, white cells, lymphocytes, neutrophils, monocytes, eosinophils, red cell parameters, hemoglobin, hematocrit, reticulocytes, platelets CBC, RBC, WBC, CHCM, EOS, HCT, HGB, LYM, MCH, MCHC, MONO, MPV, NEUT, PLT, RET, RETIC inbred  (72) both 10-13wks 2009
CGDpheno1 DXA Body mass, fat mass, lean mass, bone mineral density. None BMD inbred  (72) both 10-13wks 2009
CGDpheno1 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. None CHOL, FFA, TG inbred  (72) both 10-13wks 2009
CGDpheno1 metabolic panel Clinical blood chemistry (plasma). 4h fast. glucose, bilirubin, urea nitrogen, thyroxine, chloride, potassium, sodium, dissolved carbon dioxide BIL, CO2, GLU, T4, TBIL, chem inbred  (72) both 10-13wks 2009
Chang1 electroretinography Photoreceptor measures: rod Awave, Bwave, cone Bwave. None ERG inbred  (17) both 10-13wks 2008
Chang1 organ dimensions Eye diameter. None None inbred  (17) both 10-13wks 2008
Chen1 immune cell quantification Natural killer T cells in peripheral blood, spleen, thymus. invariant. iNK, expressing CD4 None inbred  (38) both 8-10wks 2011
Chesler5 study archive Intestinal microbiome study. microbiota, flora, gut bacteria None inbred  (10) both 2012
Cowell1 health assessment
with Staphylococcus aureus
Survival rate, Staphylococcus aureus. None None inbred  (13) f 8wks 2012
Cowell1 hormone quantification
with Staphylococcus aureus
Interleukin 6 levels (serum) after infection with Staphylococcus aureus. Kidney and peritoneal fluid. None IL-6, IL6 inbred  (13) f 8wks 2012
Cowell1 in vitro assay
with Staphylococcus aureus
Bacterial load after infection with Staphylococcus aureus. Kidney and peritoneal fluid. In vitro assay. None None inbred  (13) f 8wks 2012
Crabbe1 balance beam
with ethanol
Ethanol i.p. (several doses) vs. control (saline). Missteps count. 3 beam lengths. None EtOH inbred  (8) both 8wks 2003
Crabbe1 body weight
with ethanol
Body weight None BW inbred  (8) both 8wks 2003
Crabbe1 grid test
with ethanol
Ethanol injection (several doses) vs. control (saline). Grid habituation, missteps rate. ataxia EtOH inbred  (8) both 8wks 2003
Crabbe2 body temperature
with diazepam
Baseline vs. 30 min after diazepam injection (several doses). None None inbred  (15) both 6-7wks 1998
Crabbe2 drug and metabolite quantification
with diazepam
Diazepam (and metabolite) concentration in brain tissue immediately after diazepam injection and rotarod. None None inbred  (15) both 6-7wks 1998
Crabbe2 monitoring system
with diazepam
Locomotor activity. Baseline vs. immediately after Diazepam injection (several doses). 15 min test. None None inbred  (15) both 6-7wks 1998
Crabbe2 rotarod
with diazepam
Latency to fall from 5 rpm rotarod immediately after diazepam injection. None None inbred  (15) both 6-7wks 1998
Crabbe3 body weight
with ethanol
Body weight None BW inbred  (22) both 9-17wks 2003
Crabbe3 rotarod
with ethanol
Baseline and ethanol i.p. 3 fixed speeds (several doses) and accelerating. acquisition, improvement EtOH inbred  (22) both 9-17wks 2003
Crabbe4 alcohol quantification
with ethanol
Blood alcohol concentration after ethanol 2 g/kg i.p., several timepoints. blood alcohol concentration BAC, BEC, EtOH inbred  (21) both 9-17wks 2003
Crabbe4 dowel balance test
with ethanol
Latency to fall 0 min and 30 min post-injection, 2 widths. Ethanol 2 g/kg. None EtOH inbred  (21) both 9-17wks 2003
Crabbe4 grip strength
with ethanol
Baseline vs. 30 min after ethanol 2 g/kg i.p. None EtOH inbred  (21) both 9-17wks 2003
Crabbe4 vertical wire mesh
with ethanol
Latency to fall 30 min post-injection. Ethanol 2 g/kg i.p. None EtOH inbred  (21) both 9-17wks 2003
Crabbe5 parallel rod floor test
with ethanol
Parallel rod balance test, baseline vs. ethanol 2 g/kg i.p.. floor rod EtOH inbred  (8) both 7-14wks 2005
Crowley1 behavior observation
with haloperidol
Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). tongue protrusion, overt or subtle chewing movement, jaw tremor None inbred w/CC8  (27) m 9-28wks 2012
Crowley1 body weight
with haloperidol
Baseline vs. after haloperidol 60d implant. None BW inbred w/CC8  (27) m 9-28wks 2012
Crowley1 drug and metabolite quantification
with haloperidol
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). None None inbred w/CC8  (27) m 9-28wks 2012
Crowley1 inclined screen test
with haloperidol
Baseline vs. during and after haloperidol 60d implant (several timepoints). extrapyramidal side effects, EPS None inbred w/CC8  (27) m 9-28wks 2012
Crowley1 open field test
with haloperidol
Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. None OFT inbred w/CC8  (27) m 9-28wks 2012
Deschepper1 body weight Body weight None BW inbred  (13) both 10wks 2004
Deschepper1 organ weights Heart, kidney, thymus, adrena weightsl. None None inbred  (13) both 10wks 2004
Deschepper1 tail cuff Blood pressure. None BP inbred  (13) both 10wks 2004
Dickson1 operant conditioning chamber Sign tracking and goal tracking paradigm with Pavlovian conditioned approach. 'paired' vs. 'unpaired' conditions, incentive salience and reward cues None inbred  (5) both 12-20wks 2015
Dietrich1 in vitro assay
with Bacillus anthracis lethal toxin
Bacillus anthracis lethal toxin (anthrax) susceptibility. None None inbred  (50) f 6-8wks* 1998
DiPetrillo1 urinalysis Microalbumin, creatinine, ratio. kidney Alb, CREA, MA inbred w/CC7  (34) m 10wks 2012
Donahue1 DXA Body mass, fat mass, lean mass, bone mineral density and content, craniofacial dimensions. whole body without head, spine, skull BMD inbred w/CC7  (30) both 15-16wks 2002
Donahue1 hormone quantification Osteocalcin, insulin-like growth factor 1. None IGF-1, IGF1, INS, OC inbred w/CC7  (30) both 15-16wks 2002
Donahue1 metabolic panel Thyroxine (serum). None T4 inbred w/CC7  (30) both 15-16wks 2002
Donahue18 body weight Pup body weight at day 3. None BW inbred  (15) f 6-8wks 2010
Donahue18 colony observation Reproduction, fecundity. Litter size, percent survival to day 3. None None inbred  (15) f 6-8wks 2010
Donahue18 monitoring system Gestation duration and weight gain during pregnancy. maternal body weight BW inbred  (15) f 6-8wks 2010
Donahue2 biomechanical test Bone strength. fragility, peak maximum ultimate break load, bone break point, stiffness, bone fracture None inbred  (10) both 16wks 2004
Donahue2 body weight Body weight None BW inbred  (10) both 16wks 2004
Donahue2 bone dimensions Femur. None None inbred  (10) both 16wks 2004
Donahue2 computed tomography Bone morphology (femur). cortical thickness, cross-sectional area, circumference None inbred  (10) both 16wks 2004
Donahue2 DXA Femur bone mineral density and content, thigh cross sectional areas. volumetric density, cortical shell, cross-sectional, femur, area of thigh muscle None inbred  (10) both 16wks 2004
Donahue2 muscle weights Quadriceps muscle. None None inbred  (10) both 16wks 2004
Esposito1 histopathology Frequency rates of disorders seen during histopathology survey of various organs. adrenal gland, bladder, heart, intestine, kidney, liver, lung, ovary, pancreas, salivary gland, stomach, testis, thyroid None inbred  (6) both 2013
Eumorphia1 complete blood count Hematology. cell counts, white cells, lymphocytes, monocytes, red cell parameters, hemoglobin CBC, RBC, WBC, CHCM, HGB, LYM, MCH, MCHC, MONO inbred  (8) both 12wks 2007
Eumorphia1 lipid profile Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. Plasma. None CHOL, FFA, TG inbred  (8) both 12wks 2007
Eumorphia1 metabolic panel Clinical blood chemistry (plasma). Unknown fast. glucose, albumin, creatinine, total protein, bilirubin, urea nitrogen, iron, transferrin, alpha-amylase, uric acid, calcium, chloride, phosphorus, potassium, sodium, Alkaline phosphatase, alanine transaminase, aspartate transaminase, lactate metabolic panel inbred  (8) both 12wks 2007
Eumorphia2 DXA Body mass, fat mass, lean mass, bone mineral density and content. None BMD inbred  (5) both 12, 24, 52 wks 2008
Eumorphia3 glucose tolerance 0 to 180 min after 20% glucose i.p. 16h fast. None GLU, GTT inbred  (4) both 12, 24, 52 wks 2008
Eumorphia4 intake monitoring Food intake. Daily. None None inbred  (4) both 12, 24 wks 2008
Eumorphia5 body temperature Hourly readings in cold room. 6h test. None None inbred  (4) both 12wks 2008
Eumorphia6 echocardiography Cardiovascular function and morphology. ventricle dimension, aorta, mitral valve, fractional shortening None inbred  (4) both 12wks 2008
Eumorphia6 organ weights Cardiac ventricle weight. None None inbred  (4) both 12wks 2008
Eumorphia6 tail cuff Heart rate. None HR inbred  (4) both 12wks 2008
Eumorphia7 immunoglobulin quantification Immunoglobulin concentrations (serum). None None inbred  (6) both 9-12wks 2008
Everett1 body weight Body weight None BW inbred  (14) both 9-12wks 2003
Everett1 bone dimensions Craniofacial bone dimensions. None None inbred  (14) both 9-12wks 2003
Evsikova1 body weight Body weight None BW inbred  (14) both 25wks 2009
Evsikova1 intake monitoring Food intake, water intake at 6mo. Light phase, dark phase, total. None None inbred  (14) both 25wks 2009
Evsikova1 monitoring system Locomotor activity. Aging study. 24h test with 12h light and 12h dark phases. None None inbred  (14) both 25wks 2009
Finn1 bottle choice test Voluntary consumption of ethanol, and ethanol with saccharin (several doses in water). None EtOH inbred  (22) both 8-12wks 2007
Flaherty1 elevated zero maze Anxiety-related behaviors. None EZM inbred  (8) both 8-9wks 2001
Frankel1 electroconvulsion test
with lamotrigine
Electroconvulsive thresholds. Lamotrigine. 2 test sites. clonic, psychomotor, tonic hindlimb extension seizures, frontal and transcorneal stimulation None inbred  (16) both 6-11wks 2000
Gavras1 tail cuff
with sodium chloride
Heart rate and blood pressure. Sodium chloride (1% solution for 2wks) vs. control. None BP, HR, NaCl inbred  (11) both 9-12wks 2003
Gershenfeld1 light-dark box
with imipramine
Anxiety-related behavior. Baseline (saline) vs. imipramine i.p. 10 min test. None None inbred  (12) m 5-10wks 2003
Gershenfeld1 open field test
with imipramine
Locomotor activity, exploratory and anxiety-related behavior. Baseline (saline) vs. imipramine i.p. None OFT inbred  (12) m 5-10wks 2003
Gershenfeld1 tail suspension test
with imipramine
Immobility. Baseline (saline) vs. imipramine i.p. 6 min test. immobility time, hopelessness, depression TST inbred  (12) m 5-10wks 2003
Golani1 open field test Locomotor activity, exploratory and anxiety-related behavior. None OFT inbred  (8) m 10wks 2003
Gould1 drug and metabolite quantification
with lithium
Lithium concentration in brain tissue and blood serum after lithium (several doses). None None inbred  (11) m 7-8wks 2011
Gould1 forced swim test
with lithium
Lithium (several doses) vs. control. 6 min test. immobility time, hopelessness, depression None inbred  (11) m 7-8wks 2011
Gould2 behavior observation
with nicotine
Observed measures of anxiety. Nicotine (high dose) vs. control. 20 min period. grooming, scratching, jumping None inbred  (8) m 8-12wks 2011
Gould2 drug and metabolite quantification
with nicotine
Amount of nicotine and cotinine in blood plasma after nicotine doses. High and lower doses. cotinine None inbred  (8) m 8-12wks 2011
Gould2 elevated plus maze
with nicotine
Measures of anxiety. Nicotine (high dose) vs. control. 5 min test. None EPM inbred  (8) m 8-12wks 2011
Gould2 fear conditioning test
with nicotine
Contextual fear, cued fear. Nicotine (high and several lower doses) vs. control. None FC inbred  (8) m 8-12wks 2011
Gould3 behavior observation
with nicotine
Observed measures of anxiety during nicotine withdrawal. Nicotine (several high doses) vs. control. grooming, scratching, jumping None inbred  (8) m 8-12wks 2011
Gould3 elevated plus maze
with nicotine
Measures of anxiety during nicotine withdrawal. Nicotine (several high doses) vs. control. None EPM inbred  (8) m 8-12wks 2011
Gould3 fear conditioning test
with nicotine
Contextual fear, cued fear during nicotine withdrawal. Nicotine (high and several lower doses) vs. control. None FC inbred  (8) m 8-12wks 2011
Gould4 conditioned place preference test
with nicotine
Nicotine preference and learning effect. Nicotine-treated vs. control. 2 trials (day 5, day 10). None CPP inbred  (8) m 8-10wks 2014
Graubert1 complete blood count
with ENU
Hematology. white cells, neutrophils, lymphocytes, hemoglobin, platelets CBC, RBC, WBC, CHCM, HGB, LYM, MCH, MCHC, MPV, NEUT, PLT inbred  (20) both 9wks; 12-64wks 2006
Graubert1 histopathology
with ENU
Tumor growth frequency rates. ENU mutagen 100 mg/kg vs. control. gastrointestinal tumors, hematopoetic, lymphoid, myeloid, tumors, cancer, lung carcinoma, lung adenoma None inbred  (20) both 9wks; 12-64wks 2006
Gros1 genotype assessment
with Candida albicans
C5 allele sufficiency or deficiency. None None inbred  (36) f 8-12wks 2011
Gros1 in vitro assay
with Candida albicans
Susceptibility to infection with Candida albicans. colony-forming units in kidney, fungal load None inbred  (36) f 8-12wks 2011
Gros2 health assessment
with Plasmodium chabaudi
Survival score and susceptibility, Plasmodium chabaudi. None None inbred  (25) both 8-10wks 2012
Gros2 microscopy
with Plasmodium chabaudi
Percent of Plasmodium chabaudi-infected erythrocytes in blood. None None inbred  (25) both 8-10wks 2012
Gupta1 body weight Body weight of newborns. None BW inbred  (8) both postnatal 2011
Gupta1 organ dimensions Kidney morphology of newborns. Planar surface area. None None inbred  (8) both postnatal 2011
Gupta1 organ weights Kidney weight of newborns. None None inbred  (8) both postnatal 2011
Gupta1 renal function assay Vesico-ureteric reflux in newborns. Kidney function. urethral hydrostatic pressure, vesico ureteric reflux index, VUR None inbred  (8) both postnatal 2011
Hackstein1 immune cell quantification Respiratory dendritic cell subsets and lymphocyte populations. lung cells, bronchoalveolar lavage, dendric, leukocytes, classical and innate lymphocytes, T regulatory, CD45+, CD103+, CD19, CD80, CD90, CD3+, CD4+, CD8+, CD25, CD45, CD49 BAL, LEUK, LYM inbred  (5) m 7-11wks 2012
Hadsell1 body weight Daily body weight gain of cross-fostered pups. None BW inbred  (31) f 14-18wks 2012
Hadsell1 colony observation Maternal nurturing study. Number of pups, survival and weight gain of pups. None inbred  (31) f 14-18wks 2012
Hampton1 ECG Heart rate and wave intervals. Conscious. None ECG, EKG, HR inbred  (17) both 9-12wks 2001
Handel1 body weight Body weight None BW inbred  (14) m 8-10wks 2010
Handel1 organ weights Male reproductive organ weights. Seminal vesicles, testicles. None None inbred  (14) m 8-10wks 2010
Handel1 sperm count Sperm count. Hemocytometer. None None inbred  (14) m 8-10wks 2010
Harrill1 body weight
with isoniazid
Body weight. Isoniazid-treated vs. control. None None inbred  (34) f 8-10wks 2011
Harrill1 histopathology
with isoniazid
Liver pathology scores. Isoniazid-treated vs. control. lymphohistiocytic, hepatocytic None inbred  (34) f 8-10wks 2011
Harrill1 lipid profile
with isoniazid
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. None CHOL, TG inbred  (34) f 8-10wks 2011
Harrill1 metabolic panel
with isoniazid
Alanine transaminase. Isoniazid-treated vs. control. alanine transaminase ALT inbred  (34) f 8-10wks 2011
Harrill1 organ weights
with isoniazid
Body, liver, kidney weights. Isoniazid-treated vs. control. None None inbred  (34) f 8-10wks 2011
Harrill2 biomarker quantification
with DB289
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. None KIM-1, KIM1 inbred  (34) f 6-8wks 2012
Harrill2 body weight
with DB289
DB289-treated vs. control. None BW inbred  (34) f 6-8wks 2012
Harrill2 drug and metabolite quantification
with DB289
Kidney metabolite (DB75) concentration. DB289-treated vs. control. None None inbred  (34) f 6-8wks 2012
Harrill2 metabolic panel
with DB289
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. None ALT, BUN, CREA inbred  (34) f 6-8wks 2012
Harrill2 organ weights
with DB289
Kidney and liver weights. DB289-treated vs. control. None LW inbred  (34) f 6-8wks 2012
Harrill2 urinalysis
with DB289
Urine volume, creatinine. DB289-treated vs. control. kidney CREA inbred  (34) f 6-8wks 2012
Haston1 bronchoalveolar lavage assessment
with radiation
Bronchoalveolar cell differential after exposure to radiation (18 Gy). macrophages, lymphocytes, neutrophils, cytospin centrifuge LYM, NEUT inbred  (26) both 15-36wks 2012
Haston1 health assessment
with radiation
Survival rate and health assessment after exposure to radiation. Number of days without respiratory distress (max 26 wks). None None inbred  (26) both 15-36wks 2012
Haston1 histopathology
with radiation
Post exposure to radiation. mast cells, inflammation index None inbred  (26) both 15-36wks 2012
Hawes1 ophthalmoscopy Retinal fundoscopic examination. degeneration, coloboma, hypopigmentation, optic cup, photoreceptor None inbred w/CC7  (41) both 6-7wks 2008
Hawes1 slit lamp Eye morphology. Frequency rates of disorders. retina, cornea, iris, cataract, corneal opacity, lens synechia None inbred w/CC7  (41) both 6-7wks 2008
Hillebrands1 histopathology Kidney pathology at 20mo. perivascular immune cell clusters, aging None inbred  (23) both 87wks 2014
Jax1 body weight Body weight and growth curve from age 3wks to 10 wks, weighed weekly. None BW inbred  (24) both 8wks 2000
Jax2 MHC haplotype tissue typing Major histocompatibility complex (MHC) H2 haplotype. H2 haplotype, major histocompatibility complex MHC inbred  (56) both 2000
Jax3 colony observation Reproductive performance. age first litter, litters born, mice per litter, mice per dam, percent weaned, time intervals None inbred  (33) f various 1991
Jax4 colony observation Appearance, coat color None None inbred  (61) both 2006
Jax5 colony observation Reproductive performance. age first litter, litters born, mice per litter, mice per dam, percent weaned, time intervals, parenting index, fecundity index None inbred  (35) f various 2009
Jax6 study archive Exome genotype data. Fastq files. None None inbred  (6) m 2013
Jaxpheno1 body weight Body weight None BW inbred  (11) both 8, 16 wks 2006
Jaxpheno1 DXA Body mass, fat mass, lean mass, bone mineral density and content, bone area. None BMD, BMC inbred  (11) both 8, 16 wks 2006
Jaxpheno2 body weight Body weight None None inbred  (11) both 8, 16 wks 2006
Jaxpheno2 organ weights Brain, heart, kidney, liver, spleen weights. None None inbred  (11) both 8, 16 wks 2006
Jaxpheno3 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. None CHOL, FFA, TG inbred  (11) both 8, 16 wks 2006
Jaxpheno3 metabolic panel Clinical blood chemistry (plasma). 4h fast. glucose, urea nitrogen, thyroxine, creatinine kinase, calcium, phosphorus, alanine transaminase, albumin, total protein ALT, Alb, CK, CREA, GLU, T4, TP, chem inbred  (11) both 8, 16 wks 2006
Jaxpheno4 complete blood count Hematology. cell counts, white cells, lymphocytes, neutrophils, monocytes, basophils, eosinophils, red cell parameters, hemoglobin, hematocrit, reticulocytes, platelets BASO, CBC, RBC, WBC, CHCM, EOS, HCT, HGB, LYM, MCH, MCHC, MONO, MPV, NEUT, PLT, RET, RETIC inbred  (11) both 8, 16 wks 2006
Jaxpheno5 body weight Body weight and growth curve from age 3wks to 16wks, weighed weekly. None BW inbred  (10) both 3-16wks 2014
Jaxpheno6 body weight Body weight None BW inbred  (11) both 8, 16 wks 2006
Jaxpheno6 immune cell quantification White blood cell and immune cell differentials. granulocytes, monocytes. CD4 T cells, CD8 T cells, natural killer cells and T cells, B cells MONO inbred  (11) both 8, 16 wks 2006
Jaxpheno7 grip strength Peak tension. None None inbred  (6) m 10wks 2010
Jaxpheno7 observation (SHIRPA) Behavior, and neurosensory responses (SHIRPA protocol). wildness, aggressive behavior, vocalization None inbred  (6) m 10wks 2010
Jaxpheno7 rotarod Latency to fall from accelerating rotarod. None None inbred  (6) m 10wks 2010
Jaxpheno8 ABR test Auditory brainstem response. None ABR inbred  (7) m 10-13wks 2010
Jaxpheno8 echocardiography Cardiovascular function and morphology. ventricle dimensions, thickness, interventricular septum, volume, aortic pressure gradient, flow velocity, heart rate, ventricle performance, mitral, tricuspid HR inbred  (7) m 10-13wks 2010
Jaxwest1 body weight Body weight None BW inbred  (7) both 8-14wks 2003
Jaxwest1 DXA Body mass, fat mass, lean mass, bone mineral density and content (whole body, femur, spine). whole body without head, femur, spine BMD inbred  (7) both 8-14wks 2003
Jaxwest1 ECG Heart rate and wave intervals. Conscious. None ECG, EKG, HR inbred  (7) both 8-14wks 2003
Jaxwest1 grip strength Peak tension. None None inbred  (7) both 8-14wks 2003
Jaxwest1 nociception assay Hot plate. None HP inbred  (7) both 8-14wks 2003
Jaxwest1 tail cuff Heart rate and blood pressure. Conscious mice. None BP, HR inbred  (7) both 8-14wks 2003
Johnson1 ABR test Auditory brainstem response. None ABR inbred  (51) both 3-12wks and 15-72wks 2000
Jones1 vestibular stimulus test Vestibular function using evoked potentials. threshold stimulus response level, latency and amplitude of evoked potentials None inbred  (16) both 49-63wks 2003
Justice2 complete blood count Hematology. cell counts, white cells, lymphocytes, neutrophils, monocytes, basophils, eosinophils, red cell parameters, hemoglobin, hematocrit, platelets BASO, CBC, RBC, WBC, CHCM, EOS, HCT, HGB, LYM, MCH, MCHC, MONO, MPV, NEUT, PLT inbred  (16) both 12-16wks 2002
Kas1 balance beam Latency to reach target. None None inbred  (6) m 20-34wks 2009
Kas1 grid test Inverted grid performance. None None inbred  (6) m 20-34wks 2009
Kas1 home cage monitoring Locomotor activity. None None inbred  (6) m 20-34wks 2009
Kas1 microscopy Ventral root axon morphology. Nervous system microscopy. None None inbred  (6) m 20-34wks 2009
Klaassen1 histopathology
with cadmium
Cadmium-induced toxicity to liver, testis, trigeminal ganglia. None None inbred  (8) m 8wks 2001
Kliethermes1 hole board test Head dipping and other activity measures, hole board with and without objects in two of the holes. 10 min test. None None inbred  (14) both 8wks 2006
Kliethermes1 monitoring system Activity in a novel environment. Distance traveled, number of rears. 30 min test. None None inbred  (14) both 8wks 2006
Kliethermes1 two chamber assay Novel environment preference. Activity in familiar and novel compartments. 20 min test. None None inbred  (14) both 8wks 2006
Kliethermes1 Y-maze Spontaneous alternation. None None inbred  (14) both 8wks 2006
Korstanje1 urinalysis Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. kidney Alb, CREA, MA inbred  (30) both 52, 78, 104 wks 2008
Korstanje2 histopathology Kidney pathology. Aging study, 6mo, 12mo, 20mo. percent of glomeruli exhibiting mesangial matrix expansion None inbred  (29) m 52, 78, 104 wks 2013
Lightfoot1 body weight Body weight None BW inbred  (41) both 8-9wks 2010
Lightfoot1 running wheel monitoring Distance, duration, speed. None None inbred  (41) both 8-9wks 2010
Lionikas1 body weight
with exercise
Exercise (swim endurance training regimen) vs. control at weekly intervals for 5wks. None BW inbred  (6) m 11-14wks 2012
Lionikas1 bone dimensions
with exercise
Femur length. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. None None inbred  (6) m 11-14wks 2012
Lionikas1 microscopy
with exercise
Muscle fibers. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. None None inbred  (6) m 11-14wks 2012
Lionikas1 muscle weights
with exercise
Various muscles. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. None None inbred  (6) m 11-14wks 2012
Lionikas1 organ weights
with exercise
Heart weight. Cardiac ventricle weight. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. None None inbred  (6) m 11-14wks 2012
Lionikas1 protein activity assessment
with exercise
Muscle enzyme levels. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. citrate synthase activity, beta-hydroxyacyl-CoA dehydrogenase activity, gastrocnemius muscle None inbred  (6) m 11-14wks 2012
Lionikas1 swim endurance test
with exercise
Exercise vs. control, weekly for 5wks. None None inbred  (6) m 11-14wks 2012
Loos1 home cage monitoring Locomotor activity, avoidance, sheltering, habituation, preference index, aversion index, over several days. None None inbred  (8) m 8-19wks 2012
Loos2 home cage monitoring Locomotor activity, sheltering, habituation. 3 day home-cage assessment. None None inbred w/CC7  (11) m 8-12wks 2016
Marchuk1 histopathology Cerebral infarct volume, stroke susceptibility. Surgical occlusion of distal medial cerebral artery (MCA) to induce ischemia. cerebral infarct volume, stroke susceptibility, surgically-induced ischemia, medial cerebral artery, MCA None inbred  (16) both 11-13wks 2009
Massett1 body weight Body weight None BW inbred  (34) both 8wks 2012
Massett1 treadmill endurance test Duration, distance, work. None None inbred  (34) both 8wks 2012
Maurer1 body weight
with atenolol, isoproterenol
Isoproterenol or atenolol vs. control. None BW inbred  (23) m 10-12wks 2009
Maurer1 ECG
with atenolol, isoproterenol
Heart rate and wave amplitudes and intervals. Conscious. Isoproterenol or atenolol vs. control. None ECG, EKG, HR inbred  (23) m 10-12wks 2009
Maurer1 organ weights
with atenolol, isoproterenol
Heart, atria, ventricle weights. Isoproterenol or atenolol vs. control. None None inbred  (23) m 10-12wks 2009
Maurer1 tail cuff
with atenolol, isoproterenol
Heart rate and blood pressure. Conscious mice. Isoproterenol or atenolol vs. control. None BP, HR inbred  (23) m 10-12wks 2009
Metten1 behavior observation
with ethanol
Observed gait, hindlimb splay 10 min and 30 min after ethanol i.p. (several doses). ataxia EtOH inbred  (9) both 8-11wks 2004
Metten1 open field test
with ethanol
Locomotor activity. Ethanol i.p. (several doses) vs. control (saline i.p.). 45s test. None EtOH, OFT inbred  (9) both 8-11wks 2004
Metten2 behavior observation
with ethanol
Ethanol withdrawal severity and handling-induced convulsions. None EtOH, HIC inbred  (15) m 8-11wks 2005
Metten2 body weight
with ethanol
Body weight None BW inbred  (15) m 8-11wks 2005
Mills1 apoptosis assessment Aging study, 6mo, 12mo, 20mo. apoptotic splenocytes None inbred  (30) both 26, 52, 87 wks 2008
Mills1 chromosome instability assessment Chromosome instability. Aging study, 6mo, 12mo, 20mo. reticulocytes with micronuclei, cell damage RET, RETIC inbred  (30) both 26, 52, 87 wks 2008
Mitchell1 bottle choice test Sucrose vs. water. None None inbred  (15) m 5-7wks 2010
Mitchell1 go/no-go task Pre-cue, go cue. no-go cue. Discrimination index. None None inbred  (15) m 5-7wks 2010
Mitchell1 monitoring system Locomotor activity. None None inbred  (15) m 5-7wks 2010
Mogil1 nociception assay Battery of tests for mechanical, chemical, thermal nociception. hot plate, hot, cold, pressure on tail, von Frey, Hargreaves tests, acetic acid, magnesium sulfate, formalin, capsaicin, bee-venom, sensitivity to pain, hypersensitivity HP inbred  (12) m 6-18wks 2002
Mogil2 monitoring system Locomotor activity. Light and dark phases. None None inbred  (12) m 6-10wks 2000
Mogil3 nociception assay von Frey nociception test, baseline and after spared nerve injury (SNI) surgery as a hypersensitizer. None None inbred  (18) both 7-12wks 2012
Morgan1 body weight
with high-fat diet and olanzapine
Body weight and growth curve from age 8wks to 18wks weighed every 2wks. Olanzapine vs. control (both groups high-fat diet). None BW inbred w/CC8  (9) f 7-12wks 2014
Moy1 three chamber assay Sociability and preference for social novelty. Autism-relevant behaviors. None None inbred  (17) m 6-7wks 2008
Naggert1 body weight
with high-fat diet
High-fat diet for 8wks. None BW inbred w/CC7  (43) both 5, 21 wks 2003
Naggert1 DXA
with high-fat diet
Body mass, fat mass, lean mass, bone mineral density and content after 8wks on high-fat diet. None BMD inbred w/CC7  (43) both 5, 21 wks 2003
Naggert1 hormone quantification
with high-fat diet
Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. None INS, LEP inbred w/CC7  (43) both 5, 21 wks 2003
Naggert1 metabolic panel
with high-fat diet
Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. None GLU inbred w/CC7  (43) both 5, 21 wks 2003
Odet1 body weight Body weight None BW inbred  (8) m 10-66wks 2015
Odet1 histopathology Male reproductive histopathology. Percent normal vs. abnormal sperm, seminiferous tubules. None None inbred  (8) m 10-66wks 2015
Odet1 metabolic panel Male reproductive sperm lactate production. None None inbred  (8) m 10-66wks 2015
Odet1 organ weights Male reproductive organ weights. Testes, seminal vesicles, epididymis, vas deferens. None None inbred  (8) m 10-66wks 2015
Odet1 sperm count Sperm count. Hemocytometer. None None inbred  (8) m 10-66wks 2015
Odet2 microscopy Male reproductive sperm motility. None None inbred  (8) m 10-66wks 2015
Paigen1 body weight
with high-fat diet
Baseline vs. high-fat diet for 8wks. None BW inbred  (44) both 15-19wks 2000
Paigen1 histopathology
with high-fat diet
Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet. gallstone, mucin, arc, filaments, crystals, cholesterol monohydrate CHOL inbred  (44) both 15-19wks 2000
Paigen1 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. HDL CHOL inbred  (44) both 15-19wks 2000
Paigen1 metabolic panel
with high-fat diet
Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. alanine transaminase ALT inbred  (44) both 15-19wks 2000
Paigen1 organ dimensions
with high-fat diet
Gallbladder volume after 8wks on high-fat diet. None None inbred  (44) both 15-19wks 2000
Paigen1 organ weights
with high-fat diet
Liver weight after 8wks on high-fat diet. None LW inbred  (44) both 15-19wks 2000
Paigen2 histopathology
with high-fat diet
Aortic lesion size histopathology. Baseline vs. high-fat diet (17wks). None None inbred w/CC7  (43) both 7-9wks, 24-27wks 2002
Paigen2 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. None CHOL, TG inbred w/CC7  (43) both 7-9wks, 24-27wks 2002
Paigen4 lipid profile Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. None CHOL, TG inbred w/CC7  (43) both 10wks 2002
Perlegen2 genotyping SNP profiling, 8,100,000+ genomic locations, 1-19,X,Y,MT. None SNPs inbred  (16) m 2005
Peters1 coagulation test Fibrinogen. prothrombin time, thromboplastin time, fibrinogen. PT, PTT inbred w/CC7  (43) both 10wks 2001
Peters1 complete blood count Hematology. cell counts, white cells, lymphocytes, neutrophils, monocytes, basophils, eosinophils, large unstained cells, red cell parameters, hemoglobin, hematocrit, reticulocytes, platelets, hematology BASO, CBC, RBC, WBC, CHCM, EOS, HCT, HGB, LUC, LYM, MCH, MCHC, MONO, MPV, NEUT, PLT, RET, RETIC inbred w/CC7  (43) both 10wks 2001
Peters4 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. cell counts, white cells, lymphocytes, neutrophils, monocytes, basophils, eosinophils, large unstained cells, red cell parameters, hemoglobin, hematocrit, reticulocytes, platelets BASO, CBC, RBC, WBC, CHCM, EOS, HCT, HGB, LUC, LYM, MCH, MCHC, MONO, MPV, NEUT, PLT, RET, RETIC inbred  (30) both 26, 52, 78, 104 wks 2007
Petkova1 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. white cell count, lymphocytes, neutrophils, eosinophils, monocytes CBC, RBC, WBC, EOS, LYM, MONO, NEUT inbred  (32) both 26, 52, 78, 104 wks 2007
Petkova1 immune cell quantification Aging study, 6mo, 12mo, 18mo, 24mo. B cells. Natural killer cells, total, mature, T cells total, CD4, CD8, naive, central memory, effector cells None inbred  (32) both 26, 52, 78, 104 wks 2007
Pletcher1 body weight Body weight None BW inbred  (32) m 7-9wks 2007
Pletcher1 hormone quantification Corticosterone (serum). None None inbred  (32) m 7-9wks 2007
Pletcher1 open field test Locomotor and anxiety-related behavior. 7 min test. None OFT inbred  (32) m 7-9wks 2007
Pletcher1 tail suspension test Immobility percentage. immobility percentage, hopelessness, depression TST inbred  (32) m 7-9wks 2007
Poon1 histopathology Cell proliferation in the rostral migratory stream. BrdU+ cells. None None inbred  (9) both 13-78wks 2013
Puk1 organ dimensions Eye morphology. axial length, corneal thickness, anterior chamber depth, lens thickness None inbred  (4) both 13wks 2006
Reed1 body size and weight Body weight, body length, body mass index. None BMI, BW inbred  (28) m 8, 12 wks 2009
Reed1 fat pad weights Epididymal, retroperitoneal. None None inbred  (28) m 8, 12 wks 2009
Reed1 organ weights Heart, kidney weights. None None inbred  (28) m 8, 12 wks 2009
Rhodes1 body weight
with exercise
Exercise wheel group vs. control group. None BW inbred  (12) both 8-15wks 2010
Rhodes1 microscopy
with exercise
Examination of hippocampus dentate gyrus. Exercise wheel group vs. control group. volume, new neurons count, new neurons density None inbred  (12) both 8-15wks 2010
Rhodes1 running wheel monitoring
with exercise
Locomotor activity. Exercise wheel group vs. control group. Distance per day. None None inbred  (12) both 8-15wks 2010
Rice1 proteomic profiling Hair proteomics analysis. Spectral counts for 46 specific proteins. integumentary None inbred  (11) both 10-19wks 2012
Richfield1 neurotransmitter quantification Neurotransmitters. Molecular measures. 3-4-dihydroxyphenylacetic acid, DOPAC, 4-hydroxy-3-methoxyphenylacetic acid, HVA, serotonin, 5HT, dopamine turnover HVA, SHT inbred  (15) m 7-9wks 2003
Richfield1 open field test Locomotor activity. 3 day trials. 45 min sessions. None OFT inbred  (15) m 7-9wks 2003
RIKEN-EAD1 body size and weight Body weight, body length, tail length. None BW inbred RBRC  (56) both 8, 12 wks 2008
RIKEN-EAD1 complete blood count Hematology. cell counts, white cells, red cell parameters, hemoglobin, hematocrit, platelets CBC, RBC, WBC, CHCM, HCT, HGB, MCH, MCHC, MPV, PLT inbred RBRC  (56) both 8, 12 wks 2008
RIKEN-EAD1 lipid profile Cholesterol, HDL, triglycerides. 4h fast, plasma. None CHOL, TG inbred RBRC  (56) both 8, 12 wks 2008
RIKEN-EAD1 metabolic panel Clinical blood chemistry (plasma). 4h fast. albumin, creatinine, total protein, bilirubin, urea nitrogen, disolved carbon dioxide, calcium, chloride, magnesium, phosphorus, potassium, sodium. Alkaline phosphatase, alanine transaminase, aspartate transaminase, lipase, lactate dehydrogenase ALP, ALT, AST, Alb, BIL, CO2, CREA, LDH, LIP, TBIL, TP, chem inbred RBRC  (56) both 8, 12 wks 2008
Rusyn2 drug and metabolite quantification
with trichloroethylene
Trichloroethylene metabolites in serum, 2h, 4h, 24h after trichoroethylene exposure. dichloroacetic acid, DCA, trichloroacetic acid, TCA, DCV cyxteine, DCV glutathione DCA, TCA, TCE inbred  (17) m 7wks 2010
Rusyn2 metabolic panel
with trichloroethylene
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum). Baseline and trichloroethylene-exposed (several timepoints). No fast. None ALT, AST, BUN, TCE inbred  (17) m 7wks 2010
Rusyn5 alcohol quantification
with high-fat diet and ethanol
Alcohol concentration in blood and urine after 4 wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. None EtOH inbred  (14) m 8-14wks 2011
Rusyn5 histopathology
with high-fat diet and ethanol
Liver histopathology, injury after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. liver steatosis, inflammation, necrosis, total injury scores EtOH inbred  (14) m 8-14wks 2011
Rusyn5 lipid profile
with high-fat diet and ethanol
Hepatic triglycerides after 4wk regimen of ethanol and high-fat diet. 24h fast. None None inbred  (14) m 8-14wks 2011
Rusyn5 metabolic panel
with high-fat diet and ethanol
Alanine transaminase (serum) after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. None ALT, EtOH inbred  (14) m 8-14wks 2011
Rusyn5 metabolite quantification
with high-fat diet and ethanol
Homocysteine concentration after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. ALT, EtOH, BHMT, DDIT3, HSPA5, SREBF1, protein expression EtOH inbred  (14) m 8-14wks 2011
Rusyn5 organ weights
with high-fat diet and ethanol
Liver weight after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. None EtOH, LW inbred  (14) m 8-14wks 2011
Rusyn5 RNA expression profiling
with high-fat diet and ethanol
Liver gene expression after 4wk regimen of ethanol and high-fat diet. 24h fast. mRNA abundance relative to the control (high-fat only) group. None EtOH inbred  (14) m 8-14wks 2011
Rusyn6 drug and metabolite quantification
with trichloroethylene
Trichloroethylene metabolite in blood, liver, kidney after trichloroethylene exposure. dichloroacetic acid, DCA, trichloroacetic acid, TCA, trichloroethanol, TCOH, S-(1-2-dichlorovinyl) glutathione, DCVG, S-(1-2-dichlorovinyl)-L-cysteine, DCVC DCA, EtOH, TCA, TCE inbred  (7) m 6-7wks 2014
Rusyn6 histopathology
with trichloroethylene
Kidney histopathology evaluation after trichloroethylene exposure, relative to controls. BrdU-positive nuclei, kidney injury molecule 1, positive proximal tubules KIM-1, KIM1, TCE inbred  (7) m 6-7wks 2014
Rusyn6 metabolic panel
with trichloroethylene
Blood urea nitrogen (serum). Trichloroethylene-exposed vs. control. None BUN, TCE inbred  (7) m 6-7wks 2014
Rusyn6 organ weights
with trichloroethylene
Liver, kidney weights. Trichloroethylene-exposed vs. control. None TCE inbred  (7) m 6-7wks 2014
Rusyn6 RNA expression profiling
with trichloroethylene
Trichloroethylene effect on mRNA gene expression in liver and kidney, relative to controls. Acox1, Cyp4a10, Ppara. RT-PCR, liver and kidney mRNA gene expression TCE inbred  (7) m 6-7wks 2014
Sanger4 genotyping SNP profiling, 80,000,000+ genomic locations. SNPs and indels. 1-19,X. None SNPs inbred  (37) both 2017
Schalkwyk1 elevated plus maze Locomotor activity and exploratory behavior. 5 min test. None OFT inbred  (8) m 9-11wks 2010
Schalkwyk1 light-dark box Anxiety-related behavior. None None inbred  (8) m 9-11wks 2010
Schalkwyk1 Morris water maze Spatial learning and memory. Multiple trials. Visible platform, hidden platform, reversed platform None inbred  (8) m 9-11wks 2010
Schalkwyk1 open field test Locomotor activity and exploratory behavior. 5 min test. None OFT inbred  (8) m 9-11wks 2010
Schalkwyk1 puzzle box Learning and memory. training, burrowing task, plug task None inbred  (8) m 9-11wks 2010
Schalkwyk1 tail suspension test Duration of immobility. Two trials. immobility time, hopelessness, depression TST inbred  (8) m 9-11wks 2010
Schauwecker1 health assessment
with pilocarpine
Study of pilocarpine effect on epilepticus seizures. pilocarpine dosage, latency to onset, duration, mortality of induced seizures None inbred  (11) m 8-10wks 2012
Schonfeld1 body weight Body weight None BW inbred  (11) both 8-10wks 2005
Schonfeld1 DXA Fat mass. None None inbred  (11) both 8-10wks 2005
Schonfeld1 glucose tolerance 0 to 120 min after 10% glucose i.p. 5h fast. None GLU, GTT inbred  (11) both 8-10wks 2005
Schonfeld1 hormone quantification Insulin level, 30 min post-injection in glucose tolerance test. 10% glucose. 5h fast. None GLU, GTT, INS inbred  (11) both 8-10wks 2005
Schonfeld1 insulin tolerance 0 to 120 min after insulin i.p. 5h fast. None INS, ITT inbred  (11) both 8-10wks 2005
Schonfeld1 lipid profile Cholesterol, triglycerides, free fatty acids, phospholipids. 5h fast, plasma. Hepatic triglycerides. cholesterol, free, triglycerides, plasma, hepatic, free fatty acids, phospholipids, ester CHOL, FFA, PL, TG inbred  (11) both 8-10wks 2005
Schonfeld1 metabolic panel Glucose, beta-hydroxybutyrate (plasma). No fast. None GLU inbred  (11) both 8-10wks 2005
Schonfeld1 organ weights Liver weight. None LW inbred  (11) both 8-10wks 2005
Schughart1 body weight
with influenza A (H1N1) virus
Influenza A (H1N1) virus vs. baseline. Several timepoints. None BW, flu inbred  (9) both 10-12wks 2009
Schughart1 health assessment
with influenza A (H1N1) virus
Strain susceptibility score, influenza A (H1N1) virus. None flu inbred  (9) both 10-12wks 2009
Schughart3 body weight
with influenza A (H3N2) virus
Influenza A (H3N2) virus (several doses) vs. baseline. Several timepoints. None BW, flu inbred w/CC8  (8) both 7-13wks 2013
Schughart3 health assessment
with influenza A (H3N2) virus
Survival rate, susceptibility, influenza A (H3N2) virus (several doses). None flu inbred w/CC8  (8) both 7-13wks 2013
Schughart4 body weight
with influenza A (H3N2) virus
Influenza A (H3N2) virus vs. controls. Several timepoints. None BW, flu inbred w/CC8  (8) f 8-12wks 2016
Schughart4 complete blood count
with influenza A (H3N2) virus
White blood cell count and differentials. Influenza A (H3N2) virus vs. controls. None WBC, flu inbred w/CC8  (8) f 8-12wks 2016
Schughart4 in vitro assay
with influenza A (H3N2) virus
Viral load in lungs after infection with influenza A (H3N2) virus. None flu inbred w/CC8  (8) f 8-12wks 2016
Schughart5 body weight
with influenza A (H3N2) virus
Influenza A (H3N2) virus vs. controls. Several timepoints. None BW, flu inbred w/CC8  (8) f 8-12wks 2016
Schughart5 organ weights
with influenza A (H3N2) virus
Lung weight. Animals infected with influenza A (H3N2) virus vs. controls. None flu inbred w/CC8  (8) f 8-12wks 2016
Schulz1 body weight Body weight None None inbred  (7) both 9-18wks 2000
Schulz1 ventilator Lung, respiratory function. airway resistance, compliance, volumns, mechanics, Fowler volume, gas mixing and diffusing, airflow None inbred  (7) both 9-18wks 2000
Schwartz2 bronchoalveolar lavage assessment
with ovalbumin
Lung inflammatory changes. Ovalbumin vs. control. alveolar eosinophils, lymphocytes, neutrophils Alb, EOS, LYM, MCh, NEUT inbred  (8) m 6-8wks 2001
Schwartz3 study archive Lung, respiratory response to lipopolysaccharide endotoxin. None LPS inbred  (10) both 2003
Schwartz4 study archive Lung, respiratory response to ozone. Methacholine-sensitized. None MCh inbred  (8) both 2004
Schwartz5 study archive Lung, respiratory response to Streptococcus zooepidemicus. None None inbred  (8) both 2007
Seburn1 body weight Body weight None BW inbred  (16) both 7-9wks 2001
Seburn1 intake monitoring Food, caloric, and water intake. Daily. None None inbred  (16) both 7-9wks 2001
Seburn1 monitoring system Locomotor activity and energy metabolism. 24h test. body heat, oxygen volume, carbon dioxide volume, respiratory exchange ratio CO2, O2, RER inbred  (16) both 7-9wks 2001
Seburn2 gait analysis Aging study, 6mo, 18mo. stride length, track width, stride frequency, stance time, swing time, stride time, ratios None inbred  (32) both 26, 52, 78, 104 wks 2008
Seburn2 grip strength Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. None None inbred  (32) both 26, 52, 78, 104 wks 2008
Shin1 elevated plus maze Exploratory and anxiety-related behaviors. 5 min test. None EPM inbred  (11) m 12-14wks 2016
Shin1 fear conditioning test Pavlovian fear conditioning. None FC inbred  (11) m 12-14wks 2016
Shin1 observational fear learning test Percent time freezing to conditioning and contextual exposure. None None inbred  (11) m 12-14wks 2016
Shin1 open field test Locomotor activity and exploratory behavior. 5 min test. None OFT inbred  (11) m 12-14wks 2016
Shin1 three chamber assay Sociability testing. Tolerance of a novel mouse, a novel object, and second novel mouse vs. first. 10 min test. None None inbred  (11) m 12-14wks 2016
Shockley1 body weight
with high-fat diet
High-fat diet for 4wks vs. control. None BW inbred  (10) both 10-13wks 2008
Shockley1 lipid profile
with high-fat diet
Cholesterol, HDL, triglycerides, fatty acids. High-fat diet (4wks) vs. control. 5h fast, serum. cholesterol, HDL, triglycerides, nonesterified fatty acids CHOL, FFA, NEFA, TG inbred  (10) both 10-13wks 2008
Shockley1 metabolic panel
with high-fat diet
Clinical blood chemistry measures (serum). High-fat diet (4wks) vs. control. glucose, urea nitrogen, thyroxine, calcium, glutamate dehydrogenase GLDH, GLU, T4, chem inbred  (10) both 10-13wks 2008
Spijker2 choice serial reaction time task Choice serial reaction time task. Impulsivity, attention, cognitive flexibility behavior. 25 min test. None None inbred  (12) m 6wks 2009
Spijker2 elevated plus maze Exploratory and anxiety-related behaviors. 5 min test. None EPM inbred  (12) m 6wks 2009
Spijker2 home cage monitoring Exploratory behavior. 4 min and 10 min tests. None None inbred  (12) m 6wks 2009
Spijker2 light-dark box Anxiety, avoidance behavior. 5 min test. None None inbred  (12) m 6wks 2009
Spijker2 open field test Locomotor activity and exploratory behavior. 10 min test. None OFT inbred  (12) m 6wks 2009
Sugiyama1 tail cuff Heart rate and blood pressure. Conscious mice. None BP, HR inbred  (25) m 10wks 2007
Sundberg1 study archive Histopathology. Aging study. None None inbred  (28) both 2008
Svenson1 tail cuff Heart rate and blood pressure. Conscious mice. None BP, HR inbred  (14) both 9wks 2004
Taft1 assisted reproduction Performance following assisted reproductive technologies. in vitro ferilization, fresh embryo transfer, frozen embryo transfer, superovulation None inbred  (10) f various 2006
Tarantino1 body weight
with cocaine
Body weight None BW inbred  (45) m 8-11wks 2015
Tarantino1 open field test
with cocaine
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. None OFT inbred  (45) m 8-11wks 2015
Tarantino2 forced swim test
with ovariectomy
Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. immobility time, hopelessness, depression None inbred  (37) both 8-10wks 2016
Tarantino2 open field test
with ovariectomy
Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. None OFT inbred  (37) both 8-10wks 2016
Thomsen1 open field test
with cocaine
Locomotor activity. Baseline (saline) vs. cocaine i.p. (several doses). 1.3h and 2.3 h duration. None OFT inbred  (15) both 8-10wks 2011
Thomsen2 open field test
with quinelorane, R-6-Br-APB
Locomotor activity. Baseline (saline) vs. dopamine agonists i.p. (several doses). 3h session. R-6-Br-APB, quinelorane OFT inbred  (15) both 8-10wks 2011
Threadgill1 biomarker quantification
with acetaminophen
Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. cytochrome isoforms APAP inbred w/CC7  (37) m 8-17wks 2005
Threadgill1 histopathology
with acetaminophen
Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. None APAP inbred w/CC7  (37) m 8-17wks 2005
Threadgill1 metabolic panel
with acetaminophen
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. None ALT, APAP, AST, BUN inbred w/CC7  (37) m 8-17wks 2005
Threadgill1 metabolite quantification
with acetaminophen
Liver protein homeostasis. Acetaminophen vs. control. 18h fast. glutathione, reduced, oxidized, total, ratio APAP inbred w/CC7  (37) m 8-17wks 2005
Threadgill1 organ weights
with acetaminophen
Liver weight after acetaminophen (several doses) vs. control. 18h fast. glutathione, reduced, oxidized, total, ratio APAP, LW inbred w/CC7  (37) m 8-17wks 2005
Threadgill2 drug and metabolite quantification
with acetaminophen
Acetaminophen metabolite concentrations (serum) and liver protein homeostasis. Baseline vs. acetaminophen (several doses, several timepoints). sulfate, glucuronide, glutathione, reduced, oxidized, total APAP inbred  (5) m 6-8wks 2005
Threadgill2 histopathology
with acetaminophen
Liver histopathology, necrosis, injury after acetaminophen vs. control. 18h fast. liver injury, nitrotyrosine staining APAP inbred  (5) m 6-8wks 2005
Threadgill2 metabolic panel
with acetaminophen
Alanine transaminase (serum). Acetaminophen (several doses) vs. control. alanine transaminase ALT, APAP inbred  (5) m 6-8wks 2005
Threadgill2 metabolite quantification
with acetaminophen
Glutathione. None None inbred  (5) m 6-8wks 2005
Tomasini1 biomarker quantification Fibronectin. None None inbred  (25) both 9wks 2007
Tordoff1 body weight Body weight during testing. None BW inbred  (28) m 9wks 2001
Tordoff1 bottle choice test Various salt solutions (several concentrations) vs. water. sodium chloride, potassium chloride, calcium chloride, ammonium chloride, taste preference CaCl2, KCl, NH4Cl, NaCl inbred  (28) m 9wks 2001
Tordoff2 body weight Body weight None BW inbred  (28) m 4-12wks 2001
Tordoff2 intake monitoring Food intake, water intake. Daily. None None inbred  (28) m 4-12wks 2001
Tordoff3 body weight Body weight None BW inbred w/CC7  (40) both 9-15wks 2002
Tordoff3 bottle choice test Various salt solutions (several concentrations) vs. water. sodium chloride, calcium chloride, calcium lactate, sodium lactate, taste preference CaCl2, CaLa, NaCl, NaLa inbred w/CC7  (40) both 9-15wks 2002
Tordoff3 DXA Body mass, fat mass, lean mass, bone mineral density and content. None BMD inbred w/CC7  (40) both 9-15wks 2002
Tordoff3 metabolic panel Ionized and total blood calcium, blood pH. None None inbred w/CC7  (40) both 9-15wks 2002
Tordoff3 monitoring system Bleeding time to collect approx 30 µL. None None inbred w/CC7  (40) both 9-15wks 2002
Trullas1 elevated plus maze Exploratory and anxiety-related behaviors. 5 min test. None EPM inbred  (16) m 6-8wks 1993
Trullas1 hormone quantification Corticosterone levels (plasma). Baseline vs. after stress (30 min in restraining cage). None None inbred  (16) m 6-8wks 1993
Trullas1 monitoring system Novelty-induced fear test. Eating inhibition due to novelty of environment. 10 min test. None None inbred  (16) m 6-8wks 1993
Trullas1 open field test Locomotor activity under dim lights vs. bright lights. 5 min test. None OFT inbred  (16) m 6-8wks 1993
Vinyard1 body weight Body weight None BW inbred  (21) both 6-8wks 2009
Vinyard1 bone dimensions Craniofacial bone dimensions. maximum gape, jaw-opening, condyle None inbred  (21) both 6-8wks 2009
Vulpe1 mineral quantification Liver mineral levels. Iron, copper, zinc. Iron homeostasis. None None inbred  (18) both 8wks 2010
Vulpe1 transferrin quantification Diferric transferrin (plasma). None None inbred  (18) both 8wks 2010
Wahlsten1 elevated plus maze Locomotor, exploratory, and anxiety-related behavior. None EPM inbred  (21) both 9, 12 wks 2003
Wahlsten1 histopathology Corpus callosum, hippocampus, anterior commisure. corpus callosum, hippocampus, anterior commissure None inbred  (21) both 9, 12 wks 2003
Wahlsten1 open field test Locomotor, exploratory, and anxiety-related behavior. 5 min test. None OFT inbred  (21) both 9, 12 wks 2003
Wahlsten1 organ weights Brain weight. None None inbred  (21) both 9, 12 wks 2003
Wahlsten2 behavior observation Wildness scoring during various phenotyping tests. bites, escapes, vocalization, wildness, capture and hold None inbred  (21) both 10-12wks 2003
Williams1 immune cell quantification CD4 T cells, various populations. CD4 T cells, regulatory Treg, memory effector, naive, percent of lymphocytes LYM inbred  (5) f 8wks 2012
Willott1 acoustic startle test Acoustic startle response, prepulse inhibition. None ASR, PPI inbred w/CC7  (40) both 5-6wks 2002
Willott1 body weight Body weight None BW inbred w/CC7  (40) both 5-6wks 2002
Wiltshire1 elevated plus maze Locomotor activity. None EPM inbred  (38) both 12-14wks 2010
Wiltshire1 light-dark box Light-dark test. Anxiety-related behavior. None None inbred  (38) both 12-14wks 2010
Wiltshire1 open field test Locomotor activity. None OFT inbred  (38) both 12-14wks 2010
Wiltshire2 drug and metabolite quantification
with fluoxetine
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. None None inbred  (30) m 9-11wks 2011
Wiltshire2 open field test
with fluoxetine
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. None OFT inbred  (30) m 9-11wks 2011
Wiltshire2 tail suspension test
with fluoxetine
Immobility. Fluoxetine-treated vs. control. 5 min test. immobility time, hopelessness, depression TST inbred  (30) m 9-11wks 2011
Wiltshire3 biomarker quantification
with fluoxetine
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. cerebral cortex None inbred  (30) m 10-11wks 2011
Wiltshire4 immune cell quantification
with cancer drugs
In vitro study of 4 cancer chemotherapies vs. control. Effect on immune cells. Normalized data. B cells, T cells, monocytes, IC50. BEZ35, doxorubicin, idarubicin, selumetinib MONO inbred w/CC7  (36) m 10wks 2015
Wirth1 study archive Peripheral blood parameters. None None inbred  (8) both 2009
Xing1 ECG Heart rate and wave intervals. Conscious. Aging study, 6mo, 12mo, 20mo. None ECG, EKG, HR inbred  (29) both 26, 52, 87 wks 2008
Xing2 gait analysis Aging study, 6mo, 12mo, 18mo. None None inbred  (31) both 26, 52, 78 wks 2010
Yuan1 body weight Aging study, 6mo, 12mo, and 18mo. None BW inbred  (33) both 26, 52, 78 wks 2007
Yuan1 hormone quantification Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. None IGF-1, IGF1, INS inbred  (33) both 26, 52, 78 wks 2007
Yuan2 colony observation Life span study. Survival curves. Aging study. None None inbred  (31) both max lifespan 2007
Yuan3 lipid profile Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. None CHOL inbred  (32) both 26, 52, 78 wks 2008
Yuan3 metabolic panel Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. albumin, thyroxine, total protein, bilirubin, urea nitrogen, disolved carbon dioxide. Iron, calcium, chloride, magnesium, phosphorus, potassium, sodium. Alkaline phosphatase, alanine transaminase, lipase ALP, ALT, Alb, BIL, CO2, LIP, T4, TBIL, TP, chem inbred  (32) both 26, 52, 78 wks 2008
Yuan4 colony observation Observed age at vaginal opening (patency). Aging study. None None inbred  (33) f 2-9wks 2009
Zheng1 tympanometry Middle ear function. compliance, volume, gradient, pressure None inbred  (61) both 15-51d 2008